Renaissance Technologies (RenTech)'s XENE Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 300,500 shares of Xenon Pharmaceuticals Inc. (XENE) worth $17.47 M, representing 0.03% of the portfolio. First purchased in 2015-Q2, this long-term strategic position has been held for 40 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in XENE, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 300,500 shares. Largest reduction occurred in Q4 2021, reducing 238,200 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Xenon Pharmaceuticals (XENE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Xenon Pharmaceuticals (XENE) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +300,500 | New Buy | 300,500 | $58.15 |
| Q4 2025 | -5,200 | Sold Out | 0 | $0.00 |
| Q3 2025 | -3,400 | Reduce 39.53% | 5,200 | $40.15 |
| Q2 2025 | -146,100 | Reduce 94.44% | 8,600 | $31.30 |
| Q1 2025 | +141,000 | Add 1029.20% | 154,700 | $33.55 |
| Q4 2024 | -30,300 | Reduce 68.86% | 13,700 | $39.20 |
| Q3 2024 | -48,900 | Reduce 52.64% | 44,000 | $39.37 |
| Q2 2024 | +36,500 | Add 64.72% | 92,900 | $38.99 |
| Q1 2024 | +23,800 | Add 73.01% | 56,400 | $43.05 |
| Q4 2023 | +10,700 | Add 48.86% | 32,600 | $46.07 |
| Q3 2023 | +21,900 | New Buy | 21,900 | $34.16 |
| Q2 2022 | -150,777 | Sold Out | 0 | $0.00 |
| Q1 2022 | -230,100 | Reduce 60.41% | 150,777 | $30.57 |
| Q4 2021 | -238,200 | Reduce 38.48% | 380,877 | $31.24 |
| Q3 2021 | -38,900 | Reduce 5.91% | 619,077 | $15.28 |
| Q2 2021 | -35,000 | Reduce 5.05% | 657,977 | $18.62 |
| Q1 2021 | -77,000 | Reduce 10.00% | 692,977 | $17.90 |
| Q4 2020 | -133,300 | Reduce 14.76% | 769,977 | $15.38 |
| Q3 2020 | -132,000 | Reduce 12.75% | 903,277 | $11.07 |
| Q2 2020 | +247,200 | Add 31.37% | 1.04 M | $12.54 |
| Q1 2020 | +192,400 | Add 32.30% | 788,077 | $11.34 |
| Q4 2019 | +107,077 | Add 21.92% | 595,677 | $13.11 |
| Q3 2019 | +13,100 | Add 2.75% | 488,600 | $9.01 |
| Q2 2019 | +3,200 | Add 0.68% | 475,500 | $9.86 |
| Q1 2019 | -93,400 | Reduce 16.51% | 472,300 | $10.16 |
| Q4 2018 | +38,363 | Add 7.27% | 565,700 | $6.31 |
| Q3 2018 | +37,837 | Add 7.73% | 527,337 | $13.20 |
| Q2 2018 | +201,500 | Add 69.97% | 489,500 | $9.20 |
| Q1 2018 | +39,000 | Add 15.66% | 288,000 | $4.90 |
| Q4 2017 | +92,600 | Add 59.21% | 249,000 | $2.82 |
| Q3 2017 | +26,100 | Add 20.03% | 156,400 | $2.95 |
| Q2 2017 | -86,790 | Reduce 39.98% | 130,300 | $3.15 |
| Q1 2017 | +102,890 | Add 90.10% | 217,090 | $4.00 |
| Q4 2016 | +18,000 | Add 18.71% | 114,200 | $7.70 |
| Q3 2016 | +47,700 | Add 98.35% | 96,200 | $8.10 |
| Q2 2016 | +14,700 | Add 43.49% | 48,500 | $5.90 |
| Q1 2016 | -5,305 | Reduce 13.57% | 33,800 | $6.98 |
| Q4 2015 | +18,605 | Add 90.76% | 39,105 | $8.03 |
| Q3 2015 | -21,500 | Reduce 51.19% | 20,500 | $8.24 |
| Q2 2015 | +42,000 | New Buy | 42,000 | $11.52 |
Renaissance Technologies (RenTech)'s Xenon Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased Xenon Pharmaceuticals Inc. (XENE) in Q2 2015, acquiring 42,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Xenon Pharmaceuticals Inc. (XENE) for 40 quarters since Q2 2015.
Renaissance Technologies (RenTech)'s largest addition to Xenon Pharmaceuticals Inc. (XENE) was in Q1 2026, adding 300,500 shares worth $17.47 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 300,500 shares of Xenon Pharmaceuticals Inc. (XENE), valued at approximately $17.47 M.
As of the Q1 2026 filing, Xenon Pharmaceuticals Inc. (XENE) represents approximately 0.03% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Xenon Pharmaceuticals Inc. (XENE) was 1,035,277 shares, as reported at the end of Q2 2020.